Our work is guided by our commitment to bring new innovations to patients.
AAA is developing a pipeline of nuclear medicine theragnostic pairings for oncology indications. Our theragnostic platform involves radiolabeling a targeting molecule with fluorine 18 (F-18), gallium 68 (Ga-68), or other radionuclides used for precision radioligand imaging, or with lutetium 177 (Lu-177), actinium 225 (Ac-225) or other radionuclides used for treatment to create a targeted radioligand therapy.
Our other products include radiopharmaceuticals for molecular imaging with Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).
Look For Clinical Trials?
Find a clinical trial in your area
As part of the development process, our investigational radioligand products are evaluated in clinical trials to find new and better ways to diagnose and treat disease.
AAA is Innovating Against Cancer
Mar 25, 2020
Advanced Accelerator Applications Announces Start of Phase III Study Investigating Radioligand Therapy Lutathera®…
Jul 29, 2019
Advanced Accelerator Applications Announces State of Israel Ministry of Health Approval for Lutathera®…
Jun 5, 2019
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare®…
Feb 7, 2019